As­traZeneca spot­lights pos­i­tive PhII, PhI­II read­out for a pair of next-gen breast can­cer drugs

Two decades af­ter the FDA first ap­proved ful­ves­trant to treat a type of breast can­cer, As­traZeneca says it has gar­nered da­ta that could ush­er in a new era of treat­ment.

Two drugs are com­ing un­der the spot­light to­day. In sep­a­rate tri­als in­volv­ing dif­fer­ent sub­sets of breast can­cer pa­tients, the oral SERD camizes­trant and the AKT in­hibitor capi­vasert­ib spurred im­prove­ments in pro­gres­sion-free sur­vival.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER